Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

e, monitoring of growth in children taking GLEEVEC is recommended.

Cases of tumor lysis syndrome (TLS), including fatal cases, have been reported. The patients at risk of TLS are those with tumors having a high proliferative rate or high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

In Ph+ CML trials(****), severe (NCI Grades 3/4) lab abnormalities—including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia (<1%-33%), and hepatotoxicity (approx 5%)—and severe adverse experiences (NCI Grades 3/4), including hemorrhage (1.8%-19%), fluid retention (eg, pleural effusion, pulmonary edema, and ascites) (2.5%-11%) and superficial edema (1.5%-6%), and musculoskeletal pain (2%-9%), were reported among patients receiving GLEEVEC. Severe fluid retention appears to be dose-related, was more common in the advanced phase studies (where the dosage was 600 mg/day), and is more common in the elderly.

There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and gastrointestinal (GI) perforation.

GLEEVEC is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Significant reductions in imatinib concentrations may occur when GLEEVEC is administered concomitantly with agents that are strong CYP3A4 inducers such as rifampin, St. John's wort, and enzyme-inducing anti-epileptic drugs, eg, phenytoin. The use of concomitant strong CYP3A4 inducers should be avoided. If patients must be administered a strong CYP3A4 inducer, the dosage of GLEEVEC should be increased by at least 50% and clinical response should be carefully monitored. Caution is recommended when GLEEVEC is administered with CYP3A4 inhibitors such as ketoconazole, with CYP2D6 substrates that have a narrow therapeutic window, or with CYP3A4 substrates that have a narrow therapeutic window. Other examples of commonly used drug
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... 30, 2015   Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients ... reported financial results for the second quarter 2015. ... we remain on track to achieve our commercial and ... Officer of the Company. "Since our last quarterly earnings ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a ... technical service business units, Whitehouse Laboratories is pleased to announce that it has begun ... Container Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, ...
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Cambridge, Mass. -- May 19, 2008 -- ... have demonstrated the first room-temperature electrically-pumped semiconductor ... known as T-rays. The breakthrough in laser ... the potential to become a standard Terahertz ...
... platform expected to enable, Volcano to offer an expanded ... ... SAN DIEGO, May 19 Volcano Corporation,(Nasdaq: VOLC ), ... Tomography (OCT) products designed,to enhance the diagnosis and treatment of coronary ...
... of Ablation Therapy Using HALO System Demonstrated for, ... Progression, SAN DIEGO, May 19 Booth ... a technology leader in the design and manufacture,of ... presentation,of a landmark study entitled, "A Randomized, Multicenter, ...
Cached Biology Technology:Engineers demonstrate first room-temperature semiconductor source of coherent Terahertz radiation 2Volcano Announces Acquisition of Novelis, Inc. 2Volcano Announces Acquisition of Novelis, Inc. 3Volcano Announces Acquisition of Novelis, Inc. 4Volcano Announces Acquisition of Novelis, Inc. 5Volcano Announces Acquisition of Novelis, Inc. 6Volcano Announces Acquisition of Novelis, Inc. 7Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 2Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 3
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... For Immediate Release A group of researchers at ... Institute has published a paper that reviews new strategies ... whether people are predisposed to developing common conditions like ... age, the entire DNA sequences, or "genomes," of humans ...
... immune cell that directs other cells to fight infection ... in both health and disease. Researchers from the University ... stimulatory molecule and a protein found on the membrane ... multi-taskers of sorts. Th17 cells protect the body against ...
... ARLINGTON, Va. - To expand collaboration and initiatives, the ... be held Nov. 8-10, will explore a wide range ... explosive devices. Hosted by the Office of Naval ... Hyatt Regency in Crystal City, Va., and will feature ...
Cached Biology News:Scientists describe new approach for identifying genetic markers for common diseases 2Scientists describe new approach for identifying genetic markers for common diseases 3Penn study shows 2-sided immune cell could be harnessed to shrink tumors 2
... and parallel agitation control ,Single electronical overhead ... featuring range of stirring speeds and range ... drives can be operated as part of ... for microbiology and cell culture. ,Dimensions (D ...
... Fujifilm Life Science LAS-3000 imaging system ... a simplified user interface, providing significantly ... range of modularities. The system is ... the perfect standard system for Western ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... combines the space and time dimensions of a ... optical microscope to open new horizons in biological ... for excitation, the decay of a fluorescence emission ... decay measured. Subtle changes in the local ...
Biology Products: